Citations

Clear

65 citation(s) found for "Park, John".

Feasibility in the detection of sentinel lymph node-associated blood vessels using intravital microscopy in patients undergoing sentinel lymph node biopsy for melanoma
Gabriel, Emmanuel, Fisher, Daniel T., Kim, Minhyung , Ma, Xiaoyi , Francescutti, Valerie , Kane, John M., Evans, Sharon S. , Skitzki, Joseph J. , Attwood, Kristopher M. , Kane, John M.

Mayo Clinic

Frontiers in Imaging | March 9, 2026 | Volume: 5 | Issue: No issue available | Pages: No page available

10.3389/fimag.2026.1758694 Get It

While the clinical focus on the sentinel lymph node biopsy (SLNB) is the presence of intra- or extra-nodal metastases, preclinical studies suggest that tumor-draining SLNB-associated vascular architecture and adhesion properties are altered regardless of SLNB positivity. Human intravital microscopy (HIVM) has defined blood vessel abnormalities that may impact lymphocyte adhesion and systemic drug delivery at primary melanoma sites. In this pilot study of HIVM during melanoma SLNB, we sought to determine the feasibility of obtaining HIVM observations of SLNB-associated vessels. We successfully performed HIVM in all 20 SLNB patients, and 7 were found to have nodal micrometastases by standard pathology. HIVM was capable of identifying both functional and non-functional SLNB-associated vessels based on the presence or absence of fluorescent dye uptake, respectively. Comparing vessel characteristics as a secondary exploratory objective, no statistically significant differences were noted in the diameter, flow rate, functionality, or shear stress of SLNB-associated blood vessels between positive and negative SLNBs, which may likely have been a reflection of the minimal disease burden. Nonetheless, these initial observations provide the framework to optimize future trials of HIVM in cancer patients.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Feasibility in the Detection of Nodal Metastatic Melanoma Using Intravital Microscopy
Fisher, Daniel T., Kim, Minhyung , Ma, Xiaoyi , Francescutti, Valerie , Kane, John M. , Evans, Sharon S. , Skitzki, Joseph J. , Gabriel, Emmanuel , Attwood, Kristopher M. , Ma, Xiaoyi

Mayo Clinic

No container title available | December 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5161333/v1 Get It

Abstract While the clinical focus on the sentinel lymph node biopsy (SLNB) is the presence of intra- or extra-nodal metastases, preclinical studies suggest that tumor-draining SLNB-associated vascular architecture and adhesion properties are altered regardless of SLNB positivity. Human intravital microscopy (HIVM) has defined blood vessel abnormalities that may impact lymphocyte adhesion and systemic drug delivery at primary melanoma sites. In this pilot study of HIVM during melanoma SLNB, we sought to determine the feasibility of obtaining HIVM observations of SLNB-associated vessels. We successfully performed HIVM in all 20 SLNB patients, and 7 were found to have nodal micrometastases by standard pathology. HIVM was capable of identifying both functional and non-functional SLNB-associated vessels based on the presence or absence of fluorescent dye uptake, respectively. Comparing vessel characteristics as a secondary objective, no statistically significant differences were noted in the diameter, flow rate, functionality, or shear stress of SLNB-associated blood vessels between positive and negative SLNBs, which may likely have been a reflection of the minimal disease burden. Nonetheless, these initial observations provide the framework to optimize future trials of HIVM in cancer patients.
Strengthening Physical Medicine and Rehabilitation Departmental Research: Insights From the Association of Academic Physiatrists Research Consulting Program
Wang, Qing Mei , Lencioni, Stephen, Huber, Justin , Rizzo, John‐Ross , Scholten, Paul , Swanson, Randel L. , Schnappinger, Amy, Arnold, W David , Annaswamy, Thiru M. , Bean, Allison , Kumbhare, Dinesh Arun , Li, Sheng , Paganoni, Sabrina , Suskauer, Stacy J. , Whyte, John , Arnold, W. David

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | October 9, 2025 | Volume: 104 | Issue: 12 | Pages: 1186-1189

10.1097/phm.0000000000002769 | PMID 41065593 Get It

Abstract Clinical and translational research is important for health care and the growth of medical specialties. Physical medicine and rehabilitation offers many opportunities for research, but research growth in physical medicine and rehabilitation is lacking, and research resources and productivity vary across academic physical medicine and rehabilitation departments across North America. The Physiatric Research Consulting Program was developed by the Association of Academic Physiatrists to provide customized recommendations to enhance research capacity and productivity in physical medicine and rehabilitation departments. This report outlines the three components of the Physiatric Research Consulting Program, including a previsit needs assessment, an in-person visit, and a postvisit follow-up final report. The report also provides a qualitative assessment of the impact of the Physiatric Research Consulting Program, with general themes of feedback, site visit evaluations, and final report evaluations. The Physiatric Research Consulting Program was found to be valuable in identifying gaps and needs for physical medicine and rehabilitation departments, providing outside perspectives, and energizing faculty toward research growth in their departments.
The need for an organoid manufacturing, preservation, and distribution center
Hermanson, David, Low, Walter C. , McKenna, David H. , Palecek, Sean P. , Temenoff, Johnna S. , Ogle, Brenda M. , Ogle, Brenda M , Atala, Anthony , Bischof, John C , Chen, Christopher S. , Fisher, John P. , Howe, Charles L. , Ma, Zhen

Mayo Clinic

Stem Cells Translational Medicine | June 19, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1093/stcltm/szaf031 | PMID 40627335 Get It

Abstract Organoids, which are tiny, lab-grown 3D structures that mimic some organizational and functional properties of human organs, are slowly transforming the face of systems and developmental biology, biomedical research, pharmaceutical testing, environmental toxin testing, and healthcare. Significant investments are essential for the mass production, preservation, and distribution of organoids, with the aim to accelerate innovation and progress across multiple fields—much like the investments made in cell and biologics manufacturing over the past 2 decades.
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer
Rami, Avina , Zhong, Caiwei , Muniz, Miguel, Khorasanchi, Adam , Fein, Daniel , Stoltenberg, Hailey, Gopalakrishan, Dharmesh, Yang, Yuanquan , Ng, Thomas S.C. , Gafita, Andrei , Jacene, Heather A. , Ravi, Praful , Muniz, Miguel , Khorasanchi, Adam , Fein, Daniel , Ng, Thomas S C , Childs, Daniel S , Xie, Wanling , Gallagher, John F. , Mohammadi, Sedra, Voter, Andrew F. , Childs, Daniel S.

Mayo Clinic

Cancers | June 12, 2025 | Volume: 17 | Issue: 12 | Pages: 1960

10.3390/cancers17121960 | PMID 40563610 Get It

Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [177Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA. The primary outcomes were PSA-50 rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Statistical models were adjusted for age, number of prior therapies, sites of metastases, and baseline PSA. A total of 654 patients were included; 593 (91%) were White, 45 (7%) were Black and 16 (2%) were another non-Black minority (NBM). There were no statistically significant differences in PSA-50 rates, PSA-PFS and OS between the groups. Black and White patients treated with LuPSMA had similar clinical outcomes; efforts are needed to ensure Black and NBM patients have equal access to life prolonging therapies to narrow disparities in outcomes.
Training the next generation of intensivists: Point-of-care ultrasound
Park, John G. , Garcia, Samuel I. , Kinni, Harish

Mayo Clinic

Journal of Translational Critical Care Medicine | June 5, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1097/jtccm-d-25-00004 Get It

Point-of-care ultrasound (POCUS) is increasingly becoming integral to clinical practice across many subspecialties. Its value in diagnostics and therapeutics has been validated across various disorders. It is becoming evident that the integration of POCUS in our intensive care units is becoming essential in early diagnostics and interventions that impacts patient outcomes. Therefore, we must train our next generation of intensivists, guided by several established recommendations from multiple societies. To achieve this task, we propose that at least four crucial elements, with full support from the institutional leadership, must be established. These include sufficient number of trained staff, a comprehensive curriculum, an educational platform, and a continuous professional development program. In establishing such a program, the potential harm of misinterpretation leading to mismanagement should be mitigated.
Respiratory volume changes and CSF circulation during human NREM sleep
Lee, Jeyeon , Kandimalla, Mahathi, Ghatamaneni, Sujala, Dewan, Sannidhi, Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Yook, Soonhyun , Kim, Hosung , Park, John G. , Lowe, Val J. , Min, Hoon‐Ki , Min, Hoon-Ki Paul , Lim, Seokbeen , Thakkar, Jay, Cogswell, Petrice M. , Botha, Hugo , McCarter, Stuart J. , Louis, Erik K. St. , Mantilla, Carlos B. , Huston, John

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.093200 Get It

AbstractBackgroundSleep’s crucial role in maintaining brain health is increasingly recognized, particularly due to the rising prevalence of neurodegenerative diseases. It not only supports cognitive function but also aids in clearing brain metabolic waste through cerebrospinal fluid (CSF) dynamics. During sleep, especially in the non‐rapid eye movement (NREM) phase, CSF flow increases, essential for removing neurotoxic substances like amyloid‐beta proteins. This study explores the link between sleep respiratory patterns and CSF flow promotion.MethodElectroencephalography (EEG), and functional magnetic resonance imaging (fMRI) were simultaneously acquired during sleep from Gu, et al. (n = 29) (Gu et al. 2022). Respiration, measured via a respiratory belt, calculated respiratory volume (RV) as the standard deviation within a 5 second sliding window. EEG data processed delta band power (1‐4Hz) averaged across channels. Parcellated fMRI data using the brain template followed by the calculation of the averaged gray matter (GM) blood‐oxygen‐level‐dependent (BOLD) signal using the GM mask. CSF inflow was manually extracted from the fMRI’s bottom slice at the foramen magnum level. Subsequently, all signals were temporally aligned to the peak of the CSF inflow signal.ResultAt the time of CSF inflow (time = 0 sec. in the Figure 1A‐D), we observed an earlier increase in RV and EEG delta power, followed by changes in the GM BOLD signal (Figure 1). EEG and RV changes preceded the BOLD signal changes, which, in turn, preceded changes in CSF flow. Sensitivity to detect RV involvement during MRI varied with the placement of the respiratory belt, being least sensitive on the chest and more on the abdomen.ConclusionThese findings raise an interesting question on the role respiratory patterns during sleep, particularly in the NREM phase. Speculatively, RV change may influence CSF circulation during NREM sleep (Figure 1E). This enhancement in CSF flow is crucial for the clearance of metabolic waste from the brain, potentially reducing the risk of neurodegenerative diseases. Our findings indicate that respiratory volume may serve as a significant marker for CSF circulation during sleep.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff, Rachna T. , King, Gentry Teng , Colby, Sarah, Scott, Aaron J. , Borad, Mitesh J. , Goff, Laura W. , Matin, Khalid , Mahipal, Amit , Kalyan, Aparna, Javle, Milind , Dika, Imane El , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Guthrie, Katherine A. , Chiorean, E. Gabriela , Höchster, Howard S. , King, Gentry , Javle, Milind M , Cheema, Puneet S , Patel, Anuj , Iyer, Renuka , Kelley, R Katie , Thumar, Jaykumar , El-Khouiery, Anthony B , Chiorean, E Gabriela , Hochster, Howard , Philip, Philip , Mahipal, Amit , Borad, Mitesh J , Patel, Anuj , El-Khoueiry, Anthony B. , Philip, Philip A.

Mayo Clinic

Journal of Clinical Oncology | December 13, 2024 | Volume: 43 | Issue: 5 | Pages: 536-544

10.1200/jco-24-01383 | PMID 39671534 Get It

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
Rehabilitation Treatment Specification System: Content and Criterion Validity Across Evidence-Based Voice Therapies for Muscle Tension Dysphonia
Stan, Jarrad H. Van , Roy, Nelson , Stemple, Joseph C., Gartner-Schmidt, Jaqueline, Gillespie, Amanda I. , Duffy, Joseph R. , Turkstra, Lyn S. , Van Stan, Jarrad H , Duffy, Joseph R , Turkstra, Lyn , Roy, Nelson , Whyte, John

Mayo Clinic

American Journal of Speech-Language Pathology | April 10, 2024 | Volume: 33 | Issue: 4 | Pages: 1774-1791

10.1044/2024_ajslp-23-00362 | PMID 38597797 Get It

Purpose: Systematically improving voice therapy outcomes is challenging as the clinician actions (i.e., active ingredients) responsible for improved patient functioning (i.e., targets) are relatively unknown. The theory-driven Rehabilitation Treatment Specification System (RTSS) and standard, voice-specific terminology based on the RTSS (RTSS-Voice) may help address this problem. This qualitative study evaluated if the RTSS and RTSS-Voice can describe four evidence-based voice therapies for muscle tension dysphonia without missing critical aspects (content validity) and identify commonalities and differences across them (criterion validity). Method: Qualitative interviews were completed between the clinicians (protocol experts) who developed and/or popularized the vocal function exercises, laryngeal reposturing, circumlaryngeal massage, and conversation training therapies as well as RTSS experts to produce RTSS specifications that met two consensus criteria: (a) The protocol expert agreed that the specification represented their treatment theory, and (b) the RTSS experts agreed that the specifications correctly adhered to both the RTSS framework and the RTSS-Voice's standard terminology. Results: The RTSS and RTSS-Voice comprehensively described voice therapy variations across and within the four diverse treatment programs, needing only the addition of one new target: overall auditory-perceptual severity. Conclusions: The RTSS and RTSS-Voice exhibited strong content validity. The standard RTSS-Voice terminology helped identify, for the first time, commonalities and differences in treatment ingredients, targets, and mechanisms of action across four treatments developed for the same patient population. In the long term, the RTSS and RTSS-Voice could provide the framework for an ever-growing collection of clinically meaningful and evidence-based therapy algorithms with potential to improve research, education, and clinical care. Supplemental Material: https://doi.org/10.23641/asha.25537624